An in vitro study that used a fibroblast-derived ECM scaffold showed that FGF2, a FGFR1 ligand, mediates estrogen-independent ER signaling in breast cancer cells when bound to the ECM, rendering FGFR1 as a relevant MBD–related target (12). Here, ESR1 is linked to breast cancer.